产品简要
公司名称 :
北京义翘神州
产品类型 :
蛋白
产品名称 :
人类PD-L1/B7-H1/CD274蛋白(多聚组氨酸标签)
目录 :
10084-H08H
规格 :
100微克
价格 :
208美元
更多信息或购买 :
文章摘录数: 20
出版应用/物种/样本/稀释参考文献
  • 免疫印迹; 人类
Mahoney K, Shukla S, Patsoukis N, Chaudhri A, Browne E, Arazi A, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68:421-432 pubmed 出版商
Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, et al. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Front Immunol. 2021;12:778978 pubmed 出版商
Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536 pubmed 出版商
Sasikumar P, Sudarshan N, Adurthi S, Ramachandra R, Samiulla D, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4:699 pubmed 出版商
Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, et al. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol. 2021;12:654463 pubmed 出版商
Li M, Zhao R, Chen J, Tian W, Xia C, Liu X, et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Sci Rep. 2021;11:5774 pubmed 出版商
Wang F, Ye W, Wang S, He Y, Zhong H, Wang Y, et al. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia. 2021;23:281-293 pubmed 出版商
Schofield D, Percival Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs. 2021;13:1857100 pubmed 出版商
Gu T, Zhao S, Jin G, Song M, Zhi Y, Zhao R, et al. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Front Immunol. 2020;11:621441 pubmed 出版商
Wu X, Li F, Li Y, Yu Y, Liang C, Zhang B, et al. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Med Sci Monit. 2020;26:e925583 pubmed 出版商
Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219: pubmed 出版商
Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019;51:1059-1073.e9 pubmed 出版商
Hassounah N, Malladi V, Huang Y, Freeman S, Beauchamp E, Koyama S, et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother. 2019;68:407-420 pubmed 出版商
Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, et al. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front Immunol. 2018;9:1614 pubmed 出版商
Ansari N, Ghazvini K, Ramezani M, Shahdordizadeh M, Yazdian Robati R, Abnous K, et al. Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay. Mikrochim Acta. 2017;185:21 pubmed 出版商
Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018;6:178-188 pubmed 出版商
Haworth K, Arnold M, Pierson C, Choi K, Yeager N, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017;8:82037-82048 pubmed 出版商
Shahdordizadeh M, Taghdisi S, Sankian M, Ramezani M, Abnous K. Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro. Int Immunopharmacol. 2017;53:96-104 pubmed 出版商
Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget. 2017;8:41932-41946 pubmed 出版商
Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7:64967-64976 pubmed 出版商
图像
图像 1 :
北京义翘神州 10084-H08H 图像 1
产品信息
提示 :
Online
目录代码 :
10084-H08H
产品名称 :
人类PD-L1/B7-H1/CD274蛋白(多聚组氨酸标签)
产品类型 :
蛋白
宿主物种 :
HEK293细胞
共轭 :
C多聚组氨酸
规格 :
100微克
标价 :
208美元
基因编号 :
NP_054862.1
产品描述 :
A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with a C-terminal polyhistidine tag.
物种摘要 :
人类
别名 :
CD274
特异性 :
1. Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear range of 0.032-0.8 μg/ml. 2. Using the Octet RED System, the affinity constant (Kd) of PD-1 Protein, Human, Recombinant (Fc Tag) (Cat. 10377-H02H) bound PD-L1 Protein, Human, Recombinant (His Tag) (Cat. 10084-H08H) was 19.2nM.
纯度 :
> 98 % as determined by SDS-PAGE
缓冲液 :
Lyophilized from sterile PBS, pH 7.4
包装 :
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
储存 :
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
更多信息或购买 :
公司信息
北京义翘神州
北京市北京经济技术开发区科创十街18号院9号楼
Order@Sinobiological.com
http://www.sinobiological.cn
400-890-9989
公司总部: 中国
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务有重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。

义翘科技为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。义翘科技目前生产和销售的现货产品种类超过4.6万种,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求,并覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供“一站式”生物试剂产品和技术服务。

义翘科技的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,累计客户数量超过5,000个,品牌声誉不断累积,已成为生物试剂行业国内领先的科技公司之一。